期刊
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 39, 期 8, 页码 2923-2931出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2020.1758789
关键词
MERS CoV; polymerase; molecular dynamics simulation; molecular docking; HCV NS5b RdRp
资金
- [pro15b114s1]
MERS CoV is a new viral infection with high mortality rate and shares similarity with Hepatitis C Virus RNA dependent RNA polymerase. The study suggests using anti-polymerases as potential candidates against MERS CoV RdRp, and identifies four novel compounds as high performance inhibitors.
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), also termed camel flu, is a new viral infection that first reported in the year 2012 in the Middle East region and further spread during the last seven years. MERS CoV is characterized by its high mortality rate among different human coronaviruses. MERS CoV polymerase shares more than 20% sequence identity with the Hepatitis C Virus (HCV) Non-structural 5b (NS5b) RNA dependent RNA polymerase (RdRp). Despite the low sequence identity, the active site is conserved between the two proteins, with two consecutive aspartates that are crucial in the nucleotide transfer reaction. In this study, seven nucleotide inhibitors have been tested against MERS CoV RdRp using molecular modeling and docking simulations, from which four are novel compounds. Molecular Dynamics Simulation for 260 nanoseconds is performed on the MERS CoV RdRp model to test the effect of protein dynamics on the binding affinities to the tested nucleotide inhibitors. Results support the hypothesis of using the anti-polymerases (Anti-HCV drugs) against MERS CoV RdRp as a potent candidates. Besides four novel compounds are suggested as a seed for high performance inhibitors against MERS CoV RdRp. Communicated by Ramaswamy H. Sarma
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据